Alzheimer’s Shows Up In Blood Tests 17 Years Before The First Symptoms

Alzheimer’s Shows Up In Blood Tests 17 Years Before The First Symptoms
SHARE

Dementia, a neurodegenerative disease For 15–20 years before the onset of clinical symptoms, the Alzheimer’s disease progression remains asymptomatic. Researchers in Bochum have created an immuno-infrared sensor that can detect Alzheimer’s disease markers in the blood up to 17 years before the onset of clinical symptoms. The sensor can detect amyloid-beta protein misfolding, which is used as a biomarker. This misfolding leads to the development of distinctive deposits in the brain termed plaques as the illness develops.

 

The study

Additional research using similar single-molecule array (SIMOA) technology was published in the same journal on March 2, 2022, lending credence to the results presented here. Scientists in Saarlouis analyzed the plasma of ESTHER trial participants to look for Alzheimer’s biomarkers. The blood samples were collected and frozen between the years of 2000 and 2002.

Participants in the study ranged in age from 50 to 75 and none of them had been diagnosed with Alzheimer’s at the time of the study. Within the present investigation, 68 individuals with a diagnosis of Alzheimer’s disease throughout the 17-year follow-up were compared to 240 individuals without such a diagnosis (the control group).

The researchers led by Klaus Gerwert and Hermann Brenner set out to see whether there were any early indicators of Alzheimer’s disease in the blood samples used for the study. The immuno-infrared sensor showed a high degree of test accuracy in identifying the 68 test participants who went on to acquire Alzheimer’s disease. The researchers also looked at the P-tau181 biomarker, a potential biomarker candidate that is presently being offered in a number of studies, using the complementary, extremely sensitive SIMOA technology as a comparison.

Nevertheless, the researchers improved the test’s sensitivity in the symptom-free period by combining amyloid-beta misfolding with GFAP concentration.

This new company plans to commercialize an immuno-infrared sensor. The researchers in Bochum believe that an early diagnosis predicated on the amyloid-beta misfolding might lead to the use of Alzheimer’s medications at such an early point that they have a substantially greater impact, such as the treatment Aduhelm, which was recently authorized in the USA.


SHARE
Anna Daniels

Anna is an avid blogger with an educational background in medicine and mental health. She is a generalist with many other interests including nutrition, women's health, astronomy and photography. In her free time from work and writing, Anna enjoys nature walks, reading, and listening to jazz and classical music.

Post Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.